Skip to main content

Leukemia News (Page 5)

Related terms: Cancer, Leukemia

FDA Approves Blincyto (blinatumomab) for Precursor B-Cell Acute Lymphoblastic Leukemia

December 3, 2014 – The U.S. Food and Drug Administration today approved Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia...

FDA Approves Zydelig (idelalisib) for CLL and Lymphoma

July 23, 2014 – The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat...

FDA Approves Imbruvica (ibrutinib) to Treat Chronic Lymphocytic Leukemia

February 12, 2014 – The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) patients who have received at least one...

FDA Approves Gazyva for Chronic Lymphocytic Leukemia

November 1, 2013 – The U.S. Food and Drug Administration today approved Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic...

FDA Medwatch Alert: Iclusig (Ponatinib): Drug Safety Communication - Increased Reports Of Serious Blood Clots In Arteries And Veins

UPDATED 10/31/2013. FDA has asked, and Ariad Pharmaceuticals has agreed, to suspend marketing and sales of Iclusig (ponatinib), a leukemia chemotherapy drug, because of the risk of life-threatening b...

FDA Medwatch Alert: Iclusig (Ponatinib): Drug Safety Communication - Increased Reports Of Serious Blood Clots In Arteries And Veins

ISSUE: FDA is investigating an increasing frequency of reports of serious and life-threatening blood clots and severe narrowing of blood vessels (arteries and veins) of patients taking the leukemia ...

FDA Approves Gleevec for Children with Acute Lymphoblastic Leukemia

January 25, 2013 – The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute...

FDA Approves Iclusig to Treat Two Rare Types of Leukemia

December 14, 2012 - The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute...

FDA Approves Bosulif for Chronic Myelogenous Leukemia

September 4, 2012 – The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older...

FDA Approves Marqibo for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

August 9, 2012 – The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome...

FDA Approves Erwinaze to Treat Acute Lymphoblastic Leukemia

November 18, 2011 – The U.S. Food and Drug Administration today approved Erwinaze (asparaginase Erwinia chrysanthemi) to treat patients with acute lymphoblastic leukemia (ALL), who have developed an...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hairy Cell Leukemia, Blood Disorders

Related drug support groups

prednisone, triamcinolone, dexamethasone